FDA Class III Recall: Rising Pharmaceuticals' Timolol Maleate Ophthalmic Solution Labeling Error Exposes Supply Chain Vulnerabilities
Rising Pharmaceuticals, Inc. initiated a Class III recall for Timolol Maleate Ophthalmic Solution due to a critical labeling mix-up. A 0.25% strength bottle was incorrectly packaged in a 0.5% strength carton. This event, now terminated, underscores the imperative for robust quality control in pharmaceutical supply chains, particularly for products manufactured by FDC Limited in India and distributed nationwide across the U.S.
FDA Class III Recall: Labeling Discrepancy for Timolol Maleate Ophthalmic Solution
On November 15, 2019, Rising Pharmaceuticals, Inc., based in Saddle Brook, NJ, initiated a voluntary Class III recall for specific lots of its Timolol Maleate USP Ophthalmic Solution. This recall, designated D-1367-2020 by the FDA, stemmed from a critical labeling mix-up identified within the product's packaging. Specifically, a case intended for Timolol Maleate Sterile Ophthalmic Solution USP 0.5%, 5 mL, was found to contain an outer carton correctly labeled for the 0.5% strength, but the bottle inside contained the 0.25% strength of the same solution. This discrepancy affects Lot # 089A016, with an expiration date of December 31, 2020. The product is a human prescription drug, administered ophthalmically, and is identified by application number ANDA077259 and product NDCs 64980-513 and 64980-514. For procurement directors, this event highlights the tangible risks associated with packaging and labeling integrity, even for Class III recalls where adverse health consequences are not likely. While a Class III classification indicates a lower risk profile, the potential for incorrect dosing of an ophthalmic solution like Timolol Maleate, used for glaucoma, could lead to suboptimal therapeutic outcomes or patient confusion. Regulatory affairs heads must recognize that such errors, though seemingly minor, indicate a lapse in Good Manufacturing Practices (GMP) and can trigger significant regulatory scrutiny, requiring extensive investigation and corrective actions to prevent recurrence. This incident underscores the necessity for robust quality assurance checkpoints throughout the entire packaging process, especially when dealing with multiple strengths of the same medication.
Operational Impact and Supply Chain Nexus: Rising Pharma and FDC Limited Roles
The recall involves Rising Pharmaceuticals, Inc. as the recalling firm and distributor, operating from its Saddle Brook, NJ, facility. The actual manufacturing of the Timolol Maleate Ophthalmic Solution was performed by FDC Limited, located at B-8, MIDC Industrial Area, Waluj, Aurangbad - 431 136, Maharashtra, India. This clear delineation of roles between a U.S.-based distributor and an India-based manufacturer is crucial for supply chain VPs, as it exposes the complexities and inherent risks of global pharmaceutical sourcing. The product was distributed U.S.A. Nationwide, indicating a broad market exposure and potentially affecting numerous pharmacies and healthcare providers across the country. For business development executives, this event emphasizes the critical importance of comprehensive due diligence on contract manufacturing organizations (CMOs) like FDC Limited. Relying on international partners necessitates stringent oversight of their quality management systems, particularly concerning labeling and packaging controls for products such as Timolol Maleate. Procurement teams must assess their exposure to similar risks across their entire portfolio, especially for high-volume generic drugs with multiple strengths. The incident underscores that even seemingly straightforward processes like labeling can lead to significant regulatory actions, impacting product availability, brand reputation, and requiring considerable resources for recall management. Ensuring clear communication channels and robust audit programs with overseas manufacturers is paramount to mitigating such supply chain vulnerabilities.
Regulatory Resolution and Future Sourcing Considerations
The recall of Timolol Maleate Ophthalmic Solution, initiated by Rising Pharmaceuticals, Inc. on November 15, 2019, underwent FDA classification on June 29, 2020, and was officially terminated on August 22, 2022. The 'Terminated' status signifies that the FDA has verified that the recalling firm has completed all necessary actions to remove the product from the market and address the root cause of the labeling error. This nearly three-year timeline from initiation to termination highlights the extensive process involved in resolving regulatory issues, even for Class III recalls. For regulatory affairs heads, the termination of this recall does not erase the event from the company's compliance record. It serves as a permanent reminder of the need for continuous improvement in quality systems and rigorous adherence to GMPs. Future regulatory filings and inspections for Rising Pharmaceuticals, Inc. and its manufacturing partner, FDC Limited, will likely face heightened scrutiny regarding labeling controls and overall quality assurance. Procurement directors should factor the duration and nature of this recall into their supplier risk assessments. A terminated recall, while resolved, still indicates a past quality system failure. This reinforces the need for proactive supplier audits, robust contractual agreements that mandate compliance with U.S. FDA standards, and contingency plans for sourcing critical ophthalmic solutions like Timolol Maleate to ensure uninterrupted supply and maintain patient safety.